ArticleFrontiers in oncology2020
The Prognostic Impact of Age at Diagnosis Upon Breast Cancer of Different Immunohistochemical Subtypes: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Analysis.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Ten-year survival of women with invasive breast cancer by stage, molecular subtype, and grade combined: a population-based study.The oncologist · 2026Article
- Overall survival and prognostic factors in young women with breast cancer: a retrospective cohort study from Southern Thailand.World journal of surgical oncology · 2026Article
- Age-dependent differences in survival of patients with early breast cancer: analysis of SUCCESS A, B, C trials.Archives of gynecology and obstetrics · 2026Article
- Cell populations in human breast cancers are molecularly and biologically distinct with age.Nature aging · 2025Article
- Article
- Deciphering the transcriptomic landscape of early HRCancer communications (London, England) · 2025Article
- Correlation Between Disease-Free Survival Endpoints and Overall Survival in Elderly Patients with Early-Stage HER2-Negative Breast Cancer: A SEER-Medicare Analysis.Advances in therapy · 2025Article
- Breast cancer stage and molecular subtype distribution: real-world insights from a regional oncological center in Hungary.Discover oncology · 2024Article
- Impact of the COVID-19 pandemic on clinical presentation, treatments, and outcomes of new breast cancer patients: A retrospective multicenter cohort study.Cancer medicine · 2023Article
- 10-year survival in female breast cancer patients according to ER, PR and HER2 expression: a cancer registry population-based analysis.Journal of cancer research and clinical oncology · 2023Article
- Article
- Long-term outcomes of intraoperatively-placed applicator brachytherapy for rapid completion of breast conserving treatment: An analysis of a prospective registry data.Clinical and translational radiation oncology · 2023Article
- Immunohistochemical subtype and its relationship with 5-year overall survival in breast cancer patients.Ecancermedicalscience · 2023Article
- The disparities in prognostic prediction and annualized hazard function in different molecular subtypes between young Chinese and White American women with breast cancer.Frontiers in oncology · 2023Article
- Breast cancer subtype and clinical characteristics in women from Peru.Frontiers in oncology · 2023Article
- Do prognosis and clinicopathological features differ in young early-stage breast cancer?Frontiers in surgery · 2022Article
- Breast-Conserving Therapy Has Better Prognosis for Tumors in the Central and Nipple Portion of Breast Cancer Compared with Mastectomy: A SEER Data-Based Study.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.